Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftibuten/VNRX-7145 in renal impairment
NCT05488678Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ledaborbactam etzadroxil (5 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time Zero to Infinity and 1 more. Started Oct 2022; status: completed.
02
Drugs
ledaborbactam etzadroxil
Beyond the preview
Go deeper on NCT05488678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488678.